Equities analysts expect ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) to post $0.99 earnings per share for the current quarter, according to Zacks Investment Research. Two analysts have made estimates for ANI Pharmaceuticals’ earnings, with the highest EPS estimate coming in at $1.00 and the lowest estimate coming in at $0.98. ANI Pharmaceuticals reported earnings of $1.09 per share during the same quarter last year, which suggests a negative year over year growth rate of 9.2%. The business is expected to report its next quarterly earnings report on Thursday, November 2nd.

On average, analysts expect that ANI Pharmaceuticals will report full-year earnings of $3.87 per share for the current year, with EPS estimates ranging from $3.86 to $3.88. For the next fiscal year, analysts forecast that the firm will post earnings of $4.56 per share, with EPS estimates ranging from $4.40 to $4.71. Zacks’ EPS calculations are an average based on a survey of sell-side research analysts that follow ANI Pharmaceuticals.

ANI Pharmaceuticals (NASDAQ:ANIP) last issued its earnings results on Thursday, August 3rd. The specialty pharmaceutical company reported $0.98 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.79 by $0.19. The business had revenue of $44.80 million during the quarter, compared to analysts’ expectations of $43.20 million. ANI Pharmaceuticals had a net margin of 3.35% and a return on equity of 22.70%. The business’s revenue for the quarter was up 43.0% compared to the same quarter last year. During the same period in the previous year, the company earned $1.11 earnings per share.

Several equities analysts have issued reports on the company. Guggenheim reiterated a “buy” rating and issued a $80.00 target price on shares of ANI Pharmaceuticals in a research note on Tuesday, July 4th. Zacks Investment Research raised shares of ANI Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, July 5th. Canaccord Genuity began coverage on shares of ANI Pharmaceuticals in a research report on Monday, July 31st. They set a “buy” rating and a $60.00 price target for the company. Finally, BidaskClub lowered shares of ANI Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, August 5th. Four analysts have rated the stock with a hold rating and two have given a buy rating to the company. ANI Pharmaceuticals presently has a consensus rating of “Hold” and a consensus price target of $65.33.

ILLEGAL ACTIVITY WARNING: This piece of content was first published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this piece of content on another website, it was illegally copied and reposted in violation of U.S. & international trademark and copyright legislation. The correct version of this piece of content can be accessed at https://www.thecerbatgem.com/2017/10/04/analysts-anticipate-ani-pharmaceuticals-inc-anip-will-post-earnings-of-0-99-per-share.html.

A number of institutional investors have recently added to or reduced their stakes in ANIP. Vanguard Group Inc. grew its stake in shares of ANI Pharmaceuticals by 8.1% during the second quarter. Vanguard Group Inc. now owns 476,948 shares of the specialty pharmaceutical company’s stock worth $22,322,000 after acquiring an additional 35,722 shares during the last quarter. First Manhattan Co. raised its position in shares of ANI Pharmaceuticals by 35.3% in the 2nd quarter. First Manhattan Co. now owns 376,395 shares of the specialty pharmaceutical company’s stock valued at $17,615,000 after purchasing an additional 98,300 shares during the last quarter. Dimensional Fund Advisors LP boosted its stake in ANI Pharmaceuticals by 91.1% in the 2nd quarter. Dimensional Fund Advisors LP now owns 339,268 shares of the specialty pharmaceutical company’s stock worth $15,878,000 after purchasing an additional 161,743 shares in the last quarter. Renaissance Technologies LLC boosted its stake in ANI Pharmaceuticals by 7.0% in the 2nd quarter. Renaissance Technologies LLC now owns 297,400 shares of the specialty pharmaceutical company’s stock worth $13,918,000 after purchasing an additional 19,400 shares in the last quarter. Finally, Nomura Holdings Inc. boosted its stake in ANI Pharmaceuticals by 0.6% in the 1st quarter. Nomura Holdings Inc. now owns 208,901 shares of the specialty pharmaceutical company’s stock worth $10,352,000 after purchasing an additional 1,164 shares in the last quarter. Institutional investors own 55.86% of the company’s stock.

ANI Pharmaceuticals (NASDAQ ANIP) opened at 53.34 on Wednesday. The stock has a 50 day moving average of $48.86 and a 200 day moving average of $48.00. ANI Pharmaceuticals has a 52 week low of $42.23 and a 52 week high of $69.85. The company has a market cap of $620.77 million, a P/E ratio of 116.72 and a beta of 3.05.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc is an integrated specialty pharmaceutical company. The Company is engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The Company focuses on areas, including controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations.

Get a free copy of the Zacks research report on ANI Pharmaceuticals (ANIP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Stock Ratings for ANI Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.